Ranibizumab can be used for long-term CRVO

Article

Visual acuity and central retinal thickness in patients with central retinal vein occlusion (CRVO) have been improved with intravitreal ranibizumab treatment, according to a study published in Retina.

Visual acuity and central retinal thickness in patients with central retinal vein occlusion (CRVO) have been improved with intravitreal ranibizumab treatment, according to a study published in Retina.

A team led by Dr Louis K. Chang, Edward S. Harkness Eye Institute, New York, USA, conducted a prospective interventional case study on 35 eyes of 35 patients with CRVO. The baseline mean visual acuity of the patients was 44.2 Early Treatment Diabetic Retinopathy Study letters, with a mean central macular thickness of 638 μm. Each patient was administered 0.5 mg of intravitreal ranibizumab at baseline and twice monthly thereafter. Patients who experienced leakage during fluorescein angiography, intraretinal haemorrhage, or macular oedema by optical coherence tomography, received additional ranibizumab.

The mean visual acuity of 32 of the 35 eyes improved by 16.5 letters and macular thickness was reduced to 164 μm after 12 months. At 24 months, 24 eyes demonstrated an improved visual acuity of 17.8 letters and macular thickness was reduced to 263 μm.

The results show that intravitreal ranibizumab significantly improves visual acuity and central retinal thickness in patients with CRVO. There were no occurrences of endophthalmitis, retinal detachment, or neovascularization. The treatment can last for up to 2 years, with a minimal number of side effects reported.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.